# Singlera Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/singlera-genomics

- Industry: Biotechnology
- Headquarters: Yangzhou, China
- Website: www.singlera.com.cn
- Total disclosed funding: $278M
- Latest round: Series B (Jun 8, 2022)
- Investors on record: 25

## About

Founded in 2014 and based in Shanghai, China, Singlera Genomics Inc. is a biotechnology company that provides gene sequencing technology services. It has research centers in Shanghai and San Diego, and production bases in Yangzhou and Taizhou. The co-founder, Chairman of the board, and CEO, Jiangli Zhang, graduated from Fudan University and served as Vice President and General Manager at ThermoFisher China. In April 2023, the company signed a strategic cooperation agreement with the Huangshan Health Commission. In June 2024, Singlera raised strategic investment for more than CNY 100 million.

The company specializes in providing genetic testing solutions for cancer and genetic diseases based on molecular diagnostic technology. The services include risk assessment, early screening and diagnosis, medication guidance, and postoperative monitoring of high-incidence cancers. The product lines cover colorectal cancer, liver cancer, stomach cancer, and other fields.

The company generates revenue by providing detection solutions and products for tumors and genetic diseases.

The company will use the strategic investment for technological research and development, registered production, and commercial implementation.

## Funding rounds

- Series B, Jun 8, 2022, $45M — Sansure Biotech Inc., Qiandao Investment Fund Management, Wuxi Guojing Investment Management, Fengshi Investment, Galaxy Yuanhui Investment, Junci Investment, Hubei Best Private Equity Fund Management
- Series B, Jun 21, 2021 — VCshare.cn, Dingxin Capital, Linden Asset Group
- Series B, Dec 15, 2020, $153M — Detong Capital, China International Capital Corporation, Green Pine Capital Partners, Furong Capital, Proxima Ventures, Prosperico Ventures, FutureX Capital, Jinkong Qiyuan Capital, Huamei International Investment Group, FTZ Fund, Linden Asset Group
- Series A, Mar 27, 2018, $60M — Lilly Asia Ventures, GTJA Investment Group, Green Pine Capital Partners, Jointown Pharmaceutical Group, China UCF Group Co., Limited, Prosperico Ventures
- Series A, Aug 22, 2016, $20M — Lilly Asia Ventures, Green Pine Capital Partners, CD Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A, Series B
- CD Capital — Series A
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A
- Jointown Pharmaceutical Group — Series A
- China UCF Group Co., Limited — Series A
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series A, Series B
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series B
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series B
- FutureX Capital (https://capitalatlas.ai/funds/futurex-capital) — Series B
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series B
- Huamei International Investment Group (https://capitalatlas.ai/funds/huamei-international-investment-group) — Series B
- FTZ Fund (https://capitalatlas.ai/funds/ftz-fund) — Series B
- Linden Asset Group — Series B
- VCshare.cn — Series B
- Dingxin Capital — Series B
- Sansure Biotech Inc. — Series B
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series B
- Wuxi Guojing Investment Management (https://capitalatlas.ai/funds/wuxi-guojing-investment-management) — Series B
- Fengshi Investment (https://capitalatlas.ai/funds/fengshi-investment) — Series B
- Galaxy Yuanhui Investment — Series B
- Junci Investment (https://capitalatlas.ai/funds/junci-investment) — Series B
- Hubei Best Private Equity Fund Management (https://capitalatlas.ai/funds/hubei-best-private-equity-fund-management) — Series B